首批国家级专科医师规范化培训专业基地---武汉协和医院心血管内科简介

首批国家级专科医师规范化培训专业基地

武汉协和医院心血管内科简介

华中科技大学同济医学院附属协和医院创建于1866年，迄今已跨越3个世纪。心血管内科成立于1960年。2001年、2007年蝉联教育部“国家重点学科”，2011年被评为卫生部“国家重点临床专科”，卫生部第一批“冠心病介入诊疗培训基地”和“心律失常（消融治疗和植入器械）诊疗培训基地”，教育部“生物靶向治疗重点实验室”，国务院第一批硕士和博士学位授权单位。汇聚国内外众多著名心血管病专家及留学归国人员，现有在职医师60人，其中教授16人，副教授12人。目前拥有5个病区和CCU病房、5个亚专科，血管造影仪3套，开放病床251张、门诊诊室10个，开设心内科专家门诊、专科门诊、专病门诊和快捷门诊，2016年门诊工作量117000余人次，年收治病人11800余人次，年介入诊疗手术10800余例次，其中冠脉介入治疗2000余例次。

武汉协和医院心内科的心血管病诊疗技术与国际发展同步，拥有国际先进的诊疗设备，常规开展：①急诊和择期冠心病介入治疗、冠脉旋磨术、冠心病杂交手术、血管内超声检查、冠脉血流储备分数检测；②阵发性室上性心动过速、心房颤动、室性心动过速和室颤的射频消融治疗；③主动脉夹层介入治疗；④先天性心脏病（房间隔缺损、室间隔缺损、动脉导管未闭）封堵术；⑤二尖瓣球囊扩张术和肥厚型心肌病室间隔化学消融术；⑥永久起搏器、ICD和CRT-D植入治疗；⑦冠心病急危重症的治疗；⑧扩张型心肌病免疫吸附治疗；⑨ 复杂疑难心肌炎心肌病的诊治；⑩ 难治性高血压的诊治，是中部地区实力雄厚的心血管病诊治中心，在医疗、教学、科研和人才培养等方面的综合实力居国内先进水平。

近10年来，心内科科学研究快速发展，在心血管病免疫学、心血管分子生物学、心血管病遗传学、心脏离子通道病等研究领域居国际国内领先水平。承担国家973、863、国家重大新药创制、国家攻关项目、国家自然科学基金重点和面上项目等课题90余项，获得国家和省部级科技进步奖20余项。创办的《临床心血管病杂志》被美国化学文摘收录，主编的《心脏病学》是国内广大心血管医师喜爱的专著，廖玉华教授主编国际首部《心血管病免疫学》。历年来，共发表论文1500余篇，发表在Nat Genet.、JACC、Diabetes、ATVB、J Immunol、Hypertension、Cardiovasc Res、Heart、JMCC、JBC等SCI收录杂志论文篇共200余篇。取得众多国际领先的创新性研究成果，2006年获得具有世界首创、自主知识产权的ATR12181治疗性降压疫苗。拥有卫生部有突出贡献中青年专家1名，教育部长江学者1名，国家自然科学基金杰出青年基金获得者1名，优秀青年基金获得者1名，教育部新世纪优秀人才支持计划获得者2名。

Brief Introduction of the Department of Cardiology of Wuhan Union Hospital

The department of cardiology of Union Hospital, affiliated to Tongji Medical College of Huazhong University of Science and Technology (also known as Wuhan Union Hospital), was founded in 1960. It was one of the first batch of State council Master's degree (1979) and Doctor's degree (1981) granting units, and won the national key discipline in 2001 and 2007. In 2008, it was approved by the Ministry of Health as one of the first batch of "Coronary Heart Disease Intervention Training Base" and "Arrhythmias (catheter ablation and implantable devices) Treatment Training Base". In 2009, it was authorized to construct "Key Laboratory of Biological Targeted Therapy of Ministry of Education ". In 2011, it was also approved by the Ministry of Health as one of the first batch of State Key Clinical Specialty. Consisted of numerous famous experts of cardiology and study abroad returnees, the department developed into the medical teaching and research institution with 60 physicians, including 16 professors, 12 associate professors. It consists of 5 wards and coronary care unit (CCU), 5 sub-specialties, 263 hospital beds, and 10 outpatient consulting rooms. Since the department was founded, it has provided effective medical service to more than 100,000 patients with cardiovascular diseases domestic and overseas. In 2016, there were 117,000 outpatient visits, 11,800 discharged patients, and 10,800 cardiovascular intervention cases annually including more than 2000 percutaneous coronary intervention (PCI) cases.

For 55 years, the medical service of the department of cardiology has developed steadily and internationally, and become one of the important state-level cardiovascular treatment centers in Central China. Nowadays, it could successfully offer the following healthcare services routinely: 1) Emergency and selective PCI, coronary artery rotational atherectomy, intravascular ultrasound (IVUS), coronary artery fractional flow reserve (FFR) detection and one-step hybrid complex coronary surgery; 2) Radiofrequency ablation treatment of paroxysmal supraventricular tachycardia, atrial fibrillation, ventricular tachycardia and ventricular fibrillation; 3) Interventional treatment of aortic dissection; 4) Interventional occlusion of congenital heart disease (such as atrial septal defect, ventricular septal defect and patent ductus arteriosus); 5) Percutaneous balloon mitral valvuloplasty (PBMV) and alcohol ablation of hypertrophic cardiomyopathy; 6) Implantation of permanent cardiac pacemaker, implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy (CRT); 7) Treatment of critical conditions of coronary heart disease; 8) Immunoadsorption therapy for dilated myocardiopathy; 9) Treatment of difficult and complicated cases of myocarditis and cardiomyopathy; 10) Treatment of refractory hypertension.  

In the past decade, the scientific research of the department has developed rapidly including the fields of cardiovascular immunology, biological target therapeutics, cardiac molecular biology, genetics of cardiovascular disease, cardiovascular ion channel disease etc. It has undertaken over 90 projects funded by National "973" Program, National "863" Program, "National Key New Drug Creation ", "National Key Technologies Research and Development Program ", "National Natural Science Foundation of China (key program or general program)" and so on. It was awarded 20 "national and provincial scientific and technological progress". Journal of Clinical Cardiology sponsored by the department was included by American Chemical Abstracts. It has edited and published 20 academic monographs. Among them, Cardiology which was coedited by Professor Mao Huanyuan, Professor Yang Xintian and Cao Linsheng was very popular among cardiovascular physicians. Immunology of Cardiovascular Diseases edited by Professor Liao Yuhua was the first monograph about cardiovascular immunology in the world. To date, it has published more than 1500 thesises, among them, 200 papers was employed by SCI journals including Nat Genet, JACC, Diabetes, ATVB, J Immunol, Hypertension, Cardiovasc Res, Heart, JMCC and JBC. It also gets some of the world leading innovative research achievements, including the first invented ATR12181 hypertension vaccine in 2006. Two members of the department were awarded as Outstanding Mid-Aged Expert of the Ministry of Health, one person has been awarded the Cheung Kong Scholars of the Ministry of Education, one person was supported by National Natural Science Funds for Distinguished Young Scholar, one person was funded by National Natural Science Foundation-Outstanding Youth Foundation, and two persons were selected as New Century Mid-Aged Excellent Talent of the Ministry of Education.